Ken Griffin Tango Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,100 shares of TNGX stock, worth $10,013. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,100
Previous 2,600
19.23%
Holding current value
$10,013
Previous $22,000
4.55%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding TNGX
# of Institutions
123Shares Held
91.7MCall Options Held
3.1KPut Options Held
1.5K-
Trv Gp Iv, LLC Boston, MA16.9MShares$54.5 Million80.09% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$43.1 Million4.45% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$26.5 Million3.35% of portfolio
-
Nextech Invest Ag5.53MShares$17.9 Million6.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.02MShares$16.2 Million0.02% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $284M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...